Home CFRX
0.1616
  Price3.00%   -0.005
 
loading

ContraFect Corporation (CFRX) Stock Discussions on Social Media

- CFRX Stock on Twitter: https://twitter.com/search?q=$cfrx
- CFRX Stock on Reddit: https://www.reddit.com/search/?q=$cfrx
- CFRX Stock on SeekingAlpha: https://seekingalpha.com/symbol/CFRX
loading
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Cap:    |  Volume (24h):